<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156290">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01775592</url>
  </required_header>
  <id_info>
    <org_study_id>NIMPE - ITM</org_study_id>
    <nct_id>NCT01775592</nct_id>
  </id_info>
  <brief_title>Plasmodium Falciparum Artemisinin Resistance Vietnam</brief_title>
  <official_title>Monitoring the Efficacy of Dihydroartemisinin - Piperaquine in Patients With Uncomplicated Falciparum Malaria in Traleng Commune, Central Vietnam</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Malariology, Parasitology and Entomology, Vietnam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute of Tropical Medicine, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Malariology, Parasitology and Entomology, Vietnam</source>
  <oversight_info>
    <authority>Vietnam: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Resistance of Plasmodium falciparum toward Artemisinins, the most important drug for the
      successful treatment of malaria, has been confirmed in Cambodia. There are few reports from
      neighbouring countries about delayed parasite rates. The investigators therefore aim to
      assess parasite clearance in malaria patients in central Vietnam when treated according to
      national standard guidelines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      General objective To evaluate the efficacy of DHA-PPQ in patients with uncomplicated
      falciparum malaria in a rural area of Central Vietnam, and to assess the in vitro
      susceptibility of P.falciparum isolates to DHA and PPQ.

      Specific objectives

        1. To measure the parasite clearance time in falciparum malaria patients treated with
           DHA-PPQ.

        2. To determine the efficacy of DHA-PPQ at day 42 post-treatment.

        3. To assess the in vitro susceptibility of P.falciparum isolates towards DHA  and PPQ in
           Quang Nam Province.

        4. To compare genetic profiles of P.falciparum isolates with delayed and those with normal
           clearance times in order to identify potential markers of resistance;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Parasite clearance time</measure>
    <time_frame>Day 2-5</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>efficacy of DHA-PPQ at day 42 post-treatment in Traleng Quangnam, Vietnam</measure>
    <time_frame>Day 42</time_frame>
    <safety_issue>No</safety_issue>
    <description>treatment failure or success at day 42</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>in vitro susceptibility of P.falciparum isolates towards DHA  and PPQ in Quang Nam Province</measure>
    <time_frame>Day 3-10</time_frame>
    <safety_issue>No</safety_issue>
    <description>MarkIII in vitro test</description>
  </secondary_outcome>
  <other_outcome>
    <measure>genetic profiles of P.falciparum isolates with delayed and those with normal clearance times in order to identify potential markers of resistance</measure>
    <time_frame>1year</time_frame>
    <safety_issue>No</safety_issue>
    <description>genotyping</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Plasmodium Falciparum</condition>
  <arm_group>
    <arm_group_label>Arterakin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Number of  DHA- PPQ (Arterakin™)  tablets per day at 0hour, 8hours, 24hours, 48hours (according to age): 2 - 3  years:0.5, 0.5, 0.5, 0.5 3 - &lt; 8 years: 1.0, 1.0, 1.0, 1.0 8 - &lt; 15 years:1.5, 1.5, 1.5, 1.5
≥ 15 years:2.0, 2.0, 2.0, 2.0</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arterakin (DHA-PPQ)</intervention_name>
    <description>NA</description>
    <arm_group_label>Arterakin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age:  from 6 months of age;

          -  Fever (body temperature above 37.5C) or history of fever in the previous 24 hours;

          -  Mono-infection with P.falciparum with parasite density between 500-100,000/µl

          -  Written informed consent to participate to the trial. For patients aged less than 18
             years, an informed consent will be obtained from a parent or a guardian.

        Exclusion Criteria:

          -  Mixed malaria infection;

          -  Pregnancy or lactation (urine test for β human chorionic gonadotropin to be performed
             on any woman of child bearing age unless menstruating);

          -  Concomitant acute illness necessitating specific treatment (antibiotics);

          -  Underlying chronic severe illness (e.g. cardiac, renal, hepatic diseases, HIV/AIDS).

          -  Severe malnutrition;

          -  Danger signs:

               -  not able to drink

               -  incontrollable vomiting

               -  recent history of convulsions (&gt;1 in 24 hours)

               -  unconscious state; neurological impairment

               -  unable to sit or stand

          -  Signs of severe malaria:

               1. Cerebral malaria (unrousable coma)

               2. Severe anaemia (Htc&lt; 15%)

               3. Renal failure (serum creatinine &gt; 3 mg/dL)

               4. Pulmonary oedema;

               5. Hypoglycemia (&lt;40mg/dL)

               6. Shock (systolic BP &lt; 70 mmHg in adults, 50 in children)

               7. Spontaneous bleeding

               8. Repeat generalized convulsions

               9. Macroscopic haemoglobinuria

              10. Severe jaundice

          -  Persons who have received quinine, artemisinin or artemisinin derivatives within the
             last 7 days, 4-aminoquinolines within the last 14 days, pyrimethamine and/or
             sulfonamides within the last 28 days, or mefloquine within the last 56 days should be
             excluded from the in vitro testing
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annette Erhart, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ITM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Health Centre Tra Leng</name>
      <address>
        <city>Tra Leng</city>
        <state>Quang Nam</state>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 25, 2013</lastchanged_date>
  <firstreceived_date>January 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>P.f resistance</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
